• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Urinary Incontinence - Pipeline Review, H1 2012 Product Image

Urinary Incontinence - Pipeline Review, H1 2012

  • ID: 2075494
  • February 2012
  • 70 pages
  • Global Markets Direct

Urinary Incontinence – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, H1 2012', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. 'Urinary Incontinence - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Urinary Incontinence.
- A review of the Urinary Incontinence products under development by companies and READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Urinary Incontinence Overview
Therapeutics Development
An Overview of Pipeline Products for Urinary Incontinence
Urinary Incontinence Therapeutics under Development by Companies
Urinary Incontinence Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Urinary Incontinence Therapeutics – Products under Development by Companies
Urinary Incontinence Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Urinary Incontinence Therapeutics Development
Cook Medical Incorporated
Allergan, Inc.
Astellas Pharma Inc.
Glenmark Pharmaceuticals Ltd.
Recordati S.p.A.
Evotec Aktiengesellschaft
MediciNova, Inc.
Plethora Solutions Holdings plc
KeyNeurotek Pharmaceuticals AG
HRA Pharma, SA
FemmePharma Global Healthcare, Inc.
Beech Tree Labs, Inc.
Urinary Incontinence – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Betanis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P2X3 and P2X2/3 Antagonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RCD-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC 0422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC 1819 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC 6211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MN-246 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FP1097 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KN203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN-214868 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICES13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UISH001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Muscle Derived Cells Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V0162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urinary Incontinence Therapeutics – Drug Profile Updates
Urinary Incontinence Therapeutics – Discontinued Products
Urinary Incontinence Therapeutics - Dormant Products
Urinary Incontinence – Product Development Milestones
Featured News & Press Releases
Aug 24, 2011: Allergan Receives FDA Approval For Botox For Treatment Of Urinary Incontinence In Adults With Neurological Conditions
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence
Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB
Oct 18, 2010: Warner Chilcott Completes Acquisition of U.S. Rights to Enablex Overactive Bladder Treatment for $400 Million in Cash
Sep 24, 2010: Novartis sells US rights to the overactive bladder treatment Enablex
Sep 24, 2010: Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex Overactive Bladder Treatment for $400 Million in Cash
Sep 24, 2010: Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex
Sep 24, 2010: Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Urinary Incontinence, H1 2012
Products under Development for Urinary Incontinence – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Cook Medical Incorporated, H1 2012
Allergan, Inc., H1 2012
Astellas Pharma Inc., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Recordati S.p.A., H1 2012
Evotec Aktiengesellschaft, H1 2012
MediciNova, Inc., H1 2012
Plethora Solutions Holdings plc, H1 2012
KeyNeurotek Pharmaceuticals AG, H1 2012
HRA Pharma, SA, H1 2012
FemmePharma Global Healthcare, Inc., H1 2012
Beech Tree Labs, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Urinary Incontinence Therapeutics – Drug Profile Updates
Urinary Incontinence Therapeutics – Discontinued Products
Urinary Incontinence Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Urinary Incontinence, H1 2012
Products under Development for Urinary Incontinence – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos